These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 39110237)

  • 1. Evaluation of oral silymarin formulation efficacy in prevention of doxorubicin induced hepatotoxicity in patients with non-metastatic breast cancer.
    Fatemi Shandiz A; Karimi G; Dayyani M; Hosseini S; Elyasi S
    J Oncol Pharm Pract; 2024 Aug; ():10781552241268778. PubMed ID: 39110237
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oral silymarin formulation efficacy in management of AC-T protocol induced hepatotoxicity in breast cancer patients: A randomized, triple blind, placebo-controlled clinical trial.
    Moezian GSA; Javadinia SA; Sales SS; Fanipakdel A; Elyasi S; Karimi G
    J Oncol Pharm Pract; 2022 Jun; 28(4):827-835. PubMed ID: 33861657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
    Wah Kheong C; Nik Mustapha NR; Mahadeva S
    Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Oral Silymarin Administration on Prevention of Radiotherapy Induced Mucositis: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
    Elyasi S; Hosseini S; Niazi Moghadam MR; Aledavood SA; Karimi G
    Phytother Res; 2016 Nov; 30(11):1879-1885. PubMed ID: 27555604
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topical silymarin administration for prevention of acute radiodermatitis in breast cancer patients: A randomized, double-blind, placebo-controlled clinical trial.
    Karbasforooshan H; Hosseini S; Elyasi S; Fani Pakdel A; Karimi G
    Phytother Res; 2019 Feb; 33(2):379-386. PubMed ID: 30479044
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Silybum marianum (L.) Gaertn. (silymarin) extract supplementation on antioxidant status and hs-CRP in patients with type 2 diabetes mellitus: a randomized, triple-blind, placebo-controlled clinical trial.
    Ebrahimpour Koujan S; Gargari BP; Mobasseri M; Valizadeh H; Asghari-Jafarabadi M
    Phytomedicine; 2015 Feb; 22(2):290-6. PubMed ID: 25765835
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Effectiveness of Silymarin in the Prevention of Anti-tuberculosis Drug-induced Hepatotoxicity: A Randomized Controlled Clinical Trial.
    Talebi A; Soltani R; Khorvash F; Jouabadi SM
    Int J Prev Med; 2023; 14():48. PubMed ID: 37351038
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The hepatorenal protective effects of silymarin in cancer patients receiving chemotherapy: a randomized, placebo-controlled trial.
    Erfanian SS; Ansari H; Javanmard SH; Amini Z; Hajigholami A
    BMC Complement Med Ther; 2024 Sep; 24(1):329. PubMed ID: 39232773
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Topical Silymarin Administration for Prevention of Capecitabine-Induced Hand-Foot Syndrome: A Randomized, Double-Blinded, Placebo-Controlled Clinical Trial.
    Elyasi S; Shojaee FSR; Allahyari A; Karimi G
    Phytother Res; 2017 Sep; 31(9):1323-1329. PubMed ID: 28635153
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protective effects of silymarin on triptolide-induced acute hepatotoxicity in rats.
    Wang L; Huang QH; Li YX; Huang YF; Xie JH; Xu LQ; Dou YX; Su ZR; Zeng HF; Chen JN
    Mol Med Rep; 2018 Jan; 17(1):789-800. PubMed ID: 29115625
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Enhanced Bioavailability and Efficacy of Silymarin Solid Dispersion in Rats with Acetaminophen-Induced Hepatotoxicity.
    Song IS; Nam SJ; Jeon JH; Park SJ; Choi MK
    Pharmaceutics; 2021 Apr; 13(5):. PubMed ID: 33925040
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial to assess the safety and efficacy of silymarin on symptoms, signs and biomarkers of acute hepatitis.
    El-Kamary SS; Shardell MD; Abdel-Hamid M; Ismail S; El-Ateek M; Metwally M; Mikhail N; Hashem M; Mousa A; Aboul-Fotouh A; El-Kassas M; Esmat G; Strickland GT
    Phytomedicine; 2009 May; 16(5):391-400. PubMed ID: 19303273
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phytosomes as a Plausible Nano-Delivery System for Enhanced Oral Bioavailability and Improved Hepatoprotective Activity of Silymarin.
    Shriram RG; Moin A; Alotaibi HF; Khafagy ES; Al Saqr A; Abu Lila AS; Charyulu RN
    Pharmaceuticals (Basel); 2022 Jun; 15(7):. PubMed ID: 35890088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals.
    Eminzade S; Uraz F; Izzettin FV
    Nutr Metab (Lond); 2008 Jul; 5():18. PubMed ID: 18601745
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Silymarin as a preventive or therapeutic measure for chemotherapy and radiotherapy-induced adverse reactions: a comprehensive review of preclinical and clinical data.
    Ghodousi M; Karbasforooshan H; Arabi L; Elyasi S
    Eur J Clin Pharmacol; 2023 Jan; 79(1):15-38. PubMed ID: 36450892
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of silymarin on liver enzymes and antioxidant status in trauma patients in the intensive care unit: a randomized double blinded placebo-controlled clinical trial.
    Mirzaei E; Sabetian G; Masjedi M; Heidari R; Mirjalili M; Dehghanian A; Vazin A
    Clin Exp Hepatol; 2021 Jun; 7(2):149-155. PubMed ID: 34295981
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of Prophylactic Use of Silymarin on Anti-tuberculosis Drugs Induced Hepatotoxicity.
    Heo E; Kim DK; Oh SH; Lee JK; Park JH; Chung HS
    Tuberc Respir Dis (Seoul); 2017 Jul; 80(3):265-269. PubMed ID: 28747959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of silymarin nanoemulsion against carbon tetrachloride-induced hepatic damage.
    Parveen R; Baboota S; Ali J; Ahuja A; Vasudev SS; Ahmad S
    Arch Pharm Res; 2011 May; 34(5):767-74. PubMed ID: 21656362
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of silymarin in patients with non-alcoholic fatty liver disease - the Siliver trial: a study protocol for a randomized controlled clinical trial.
    de Avelar CR; Nunes BVC; da Silva Sassaki B; Dos Santos Vasconcelos M; de Oliveira LPM; Lyra AC; Bueno AA; de Jesus RP
    Trials; 2023 Mar; 24(1):177. PubMed ID: 36899430
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silymarin liposomes improves oral bioavailability of silybin besides targeting hepatocytes, and immune cells.
    Kumar N; Rai A; Reddy ND; Raj PV; Jain P; Deshpande P; Mathew G; Kutty NG; Udupa N; Rao CM
    Pharmacol Rep; 2014 Oct; 66(5):788-98. PubMed ID: 25149982
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.